eFFECTOR Therapeutics, Inc.
EFTR
$0.0002
$0.000.00%
OTC PK
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -78.83% | -43.91% | 148.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -78.83% | -43.91% | 148.46% |
| Cost of Revenue | -19.37% | -1.69% | 1.90% | 15.50% | 44.14% |
| Gross Profit | 7.06% | -15.99% | -14.86% | -24.24% | -35.45% |
| SG&A Expenses | -8.62% | -13.59% | -31.24% | -27.97% | -21.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.02% | -5.87% | -11.78% | -3.62% | 14.08% |
| Operating Income | 7.59% | -4.45% | 5.86% | 0.51% | -8.20% |
| Income Before Tax | 3.12% | -58.00% | -736.80% | -254.46% | -240.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.12% | -58.00% | -736.80% | -254.46% | -240.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.12% | -58.00% | -736.80% | -254.46% | -240.47% |
| EBIT | 7.59% | -4.45% | 5.86% | 0.51% | -8.20% |
| EBITDA | 7.71% | -4.28% | 6.07% | 0.73% | -8.04% |
| EPS Basic | 38.17% | -24.92% | -625.83% | -195.38% | 68.64% |
| Normalized Basic EPS | 40.46% | 18.94% | 16.31% | 28.68% | 81.54% |
| EPS Diluted | 38.30% | -23.35% | -823.72% | -213.82% | 70.20% |
| Normalized Diluted EPS | 40.46% | 17.87% | 13.27% | 20.77% | 81.06% |
| Average Basic Shares Outstanding | 67.84% | 32.56% | 18.13% | 24.11% | 66.90% |
| Average Diluted Shares Outstanding | 67.84% | 30.55% | 14.20% | 16.57% | 53.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |